Core Viewpoint - Future Health Technology Co., Ltd. (referred to as "Future Health" or "SKG") has faced multiple setbacks in its attempts to go public, raising questions about its sincerity and business model as it prepares for its third IPO attempt after withdrawing its application from the ChiNext and terminating its North Exchange guidance [1][2]. Group 1: Financial Performance and Challenges - SKG's core product, the "smart soothing wearable device," has seen stagnant revenue growth, with income of 630 million yuan in the first three quarters of 2025, reflecting only a 0.2% year-on-year increase [3][4]. - The company's total revenue grew by 16.22% to 878 million yuan in the first nine months of 2025, but the core product's revenue growth has stalled, indicating a potential decline in consumer demand [3][4]. - SKG's cumulative dividends reached 280 million yuan, accounting for 74% of its net profit during the reporting period, raising concerns about its financial management and intentions [7][9]. Group 2: Marketing and Consumer Complaints - Despite a decline in revenue, SKG has maintained high marketing expenditures, with sales expenses in the first nine months of 2025 reaching 22.6% of total revenue, significantly higher than industry standards [10][12]. - The company has faced over 300 complaints regarding product quality and safety, with issues such as severe burns and pricing discrepancies being highlighted by consumers [15][17]. - SKG's after-sales service has been criticized for inefficiency, with consumers reporting difficulties in resolving product issues, which may undermine the brand's long-term reputation [18]. Group 3: Research and Development - SKG's investment in research and development has decreased, with R&D expenditure as a percentage of revenue falling from 9.1% in 2022 to 6.6% by the end of September 2025, contradicting its claims of being a technology-driven company [10][12]. - The company's focus on marketing over product development raises concerns about its ability to sustain growth and innovation in a competitive market [10][12].
左手借债,右手分红,SKG上演IPO“帽子戏法”
凤凰网财经·2025-12-20 13:04